What is the most specific marker of glioblastoma. Where this biomarker science leaning toward?
hi
Diagnostic biomarkers for glioma : 1- YKL-40 2- GFAP 3- MMP-9
Therapeutic targets for glioma : MGMT / EGFR / PDGFR / mTOR /HDAC/COX-2
Although significant progress has been made in the development and evaluation of diagnostic,
prognostic and predictive markers for GBM, no established clinical CSF or serum marker
exists. However, GFAP in serum seems to be a promising preoperative diagnostic marker. In
CSF, MIC-1/GDF15 and prominin-1/CD133 particle might be worth evaluating in trials to
further validate their potential as prognostic GBM markers. Distinct improvements have been
made concerning genetic GBM marker. MGMT promoter hypermethylation has been
established as an important prognostic marker and has strong influence nowadays in every
trial evaluating new therapeutic treatments. Furthermore, IDH1 became one of the most
important prognostic markers for diffusely infiltrating gliomas. Those patients who exhibit IDH1mutations have a better clinical course than patients with pGBM without mutations. The
most frequent IDH1 mutational variant R132H can be easily and reliably detected by
immunohistochemistry, which might facilitate the diagnostic procedure and may influence the
upcoming WHO classification.
hi
Diagnostic biomarkers for glioma : 1- YKL-40 2- GFAP 3- MMP-9
Therapeutic targets for glioma : MGMT / EGFR / PDGFR / mTOR /HDAC/COX-2
Although significant progress has been made in the development and evaluation of diagnostic,
prognostic and predictive markers for GBM, no established clinical CSF or serum marker
exists. However, GFAP in serum seems to be a promising preoperative diagnostic marker. In
CSF, MIC-1/GDF15 and prominin-1/CD133 particle might be worth evaluating in trials to
further validate their potential as prognostic GBM markers. Distinct improvements have been
made concerning genetic GBM marker. MGMT promoter hypermethylation has been
established as an important prognostic marker and has strong influence nowadays in every
trial evaluating new therapeutic treatments. Furthermore, IDH1 became one of the most
important prognostic markers for diffusely infiltrating gliomas. Those patients who exhibit IDH1mutations have a better clinical course than patients with pGBM without mutations. The
most frequent IDH1 mutational variant R132H can be easily and reliably detected by
immunohistochemistry, which might facilitate the diagnostic procedure and may influence the
upcoming WHO classification.
I fully agrees with Reza's responses / comments.
You must clearly "subdivide" the terms biomarkers in:
- diagnosis (GFAP is a specific marker of astroglioma, but can also be overexpressed in reactive astrocytes)
- prognosis
- treatment responses,
- etc..
the attached articles could may be of help for you.
Best regards
Robert
- Badges
- Science topic
- Similar topics
- Medicine
- Oncology
- Cancer Research